

SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following completion of the [REDACTED] (assuming the [REDACTED] is not exercised), the following persons are expected to have an interest and/or short positions in our Shares or underlying Shares which would fall to be disclosed to us and the Stock Exchange pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, will be, directly or indirectly, entitled to exercise, or control the exercise of, 10% or more of the voting power at any general meeting of our Company:

Name	Nature of interest ⁽¹⁾	Shares held immediately before completion of the [REDACTED]		Shares held immediately following completion of the Share Subdivision and the [REDACTED]	
		Number of Shares	Approximate percentage of interest in our Company	Number of Shares (as adjusted by the Share Subdivision)	Approximate percentage of interest in our Company
Dr. Zhang ⁽²⁾	Beneficial owner	153,463	0.35%	767,315	[REDACTED]%
	Interest in controlled corporation	10,250,000	23.66%	51,250,000	[REDACTED]%
Dr. Zhong ⁽²⁾	Interest in controlled corporation	10,250,000	23.66%	51,250,000	[REDACTED]%
Tyligand Holdings ⁽²⁾	Beneficial owner	10,250,000	23.66%	51,250,000	[REDACTED]%
Dr. SHI Yi (“Dr. Shi”) ⁽³⁾ .	Interest in controlled corporation	7,011,080	16.18%	35,055,400	[REDACTED]%
LAV Fund VI, L.P. (“LAV VI”) ⁽³⁾	Beneficial owner	3,505,540	8.09%	17,527,700	[REDACTED]%
LAV Fund VI Opportunities, L.P. (“LAV Opportunities”) ⁽³⁾	Beneficial owner	3,505,540	8.09%	17,527,700	[REDACTED]%
Tencent Holdings Limited ⁽⁴⁾	Interest in controlled corporation	4,883,027	11.27%	24,415,135	[REDACTED]%
Tencent Mobility ⁽⁴⁾	Beneficial owner	4,883,027	11.27%	24,415,135	[REDACTED]%
China Medical System Holdings Limited (康哲藥業控股有限公司) ⁽⁵⁾ . .	Interest in controlled corporation	3,597,306	8.30%	17,986,530	[REDACTED]%
CMS Medical ⁽⁵⁾	Beneficial owner	3,597,306	8.30%	17,986,530	[REDACTED]%
Dr. CHEN Fei ⁽⁶⁾	Interest in controlled corporation	3,505,540	8.09%	17,527,700	[REDACTED]%
Shanghai Lizhe ⁽⁶⁾	Beneficial owner	3,505,540	8.09%	17,527,700	[REDACTED]%

Notes:

- (1) All interests stated are long positions.
- (2) As of the Latest Practicable Date, Tyligand Holdings is held as to 48.75%, 41.25%, and 10.00% by Dr. Zhang, Dr. Zhong and Dr. ZY. Zhang. Therefore, each of Dr. Zhang and Dr. Zhong is deemed to be interested in the Shares held by Tyligand Holdings under the SFO.
- (3) Each of LAV VI and LAV Opportunities is a Cayman Islands exempted limited partnership. As of the Latest Practicable Date, the general partner of LAV VI is LAV GP VI, L.P., whose general partner is LAV Corporate VI GP, Ltd., a Cayman Islands exempted company wholly owned by Dr. Shi.

SUBSTANTIAL SHAREHOLDERS

As of the Latest Practicable Date, the general partner of LAV Opportunities is LAV GP VI Opportunities, L.P., whose general partner is LAV Corporate VI GP Opportunities, Ltd., a Cayman Islands exempted company wholly owned by Dr. Shi.

Therefore, each of LAV GP VI, L.P., LAV Corporate VI GP, Ltd. and Dr. Shi is deemed to be interested in the Shares held by LAV VI, and each of LAV GP VI Opportunities, L.P., LAV Corporate VI GP Opportunities, Ltd. and Dr. Shi is deemed to be interested in the Shares held by LAV Opportunities under the SFO.

- (4) As of the Latest Practicable Date, Tencent Mobility is wholly owned by Tencent Holdings Limited (騰訊控股有限公司), a company listed on the Main Board of the Stock Exchange (stock code: 00700 (HKD Counter) and 80700 (RMB Counter)). Therefore, Tencent Holdings Limited is deemed to be interested in the Shares held by Tencent Mobility under the SFO.
- (5) As of the Latest Practicable Date, CMS Medical is ultimately controlled by China Medical System Holdings Limited (康哲藥業控股有限公司), a company listed on the Stock Exchange (stock code: 867) and on the Singapore Stock Exchange (stock code: 8A8). Therefore, China Medical System Holdings Limited is deemed to be interested in the Shares held by CMS Medical under the SFO.
- (6) As of the Latest Practicable Date, the general partner of Shanghai Lizhe is Shanghai Likun Enterprise Management Partnership (Limited Partnership) (上海禮堃企業管理合夥企業(有限合夥)) (“**Shanghai Likun**”). The general partner of Likun is Shanghai Liyao Investment Management Co., Ltd. (上海禮曜投資管理有限公司) (“**Shanghai Liyao**”), which is in turn wholly owned by Dr. CHEN Fei. The sole limited partner of Shanghai Lizhe is Suzhou Lirun Equity Investment Centre (LP) (蘇州禮潤股權投資中心(有限合夥)) (“**Suzhou Lirun**”). The general partner of Suzhou Lirun is Shanghai Likun. No limited partner of Suzhou Lirun holds more than 30% interests. The general partner of Shanghai Likun is Shanghai Liyao. Therefore, each of Shanghai Likun, Suzhou Lirun, Shanghai Liyao, and Dr. CHEN Fei is deemed to be interested in the Shares held by Shanghai Lizhe under the SFO.

Save as otherwise disclosed herein, our Directors are not aware of any persons who will, immediately following completion of the [REDACTED] (assuming the [REDACTED] is not exercised), have any interests and/or short positions in the Shares or underlying Shares which would fall to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO or, will be, directly or indirectly, entitled to exercise, or control the exercise of, 10% or more of the voting power at any general meeting of our Company.